Sweden Subsidised Phesgo in Both Early and Metastatic Breast Cancer as Pertuzumab Biosimilars Approach
- Sweden’s Dental and Pharmaceutical Benefits Agency (TLV) has included Roche‘s Phesgo, a fixed-dose subcutaneous combination of pertuzumab and trastuzumab, in the national high-cost protection scheme with general subsidy from 29 September 2026.
- In TLV’s analysis, the cost per quality-adjusted life year for Phesgo falls below the level TLV usually accepts for conditions of high severity, which covers adjuvant treatment of early breast cancer, and of very high severity, which covers metastatic breast cancer. TLV judged the costs reasonable in both settings.
- TLV’s decision text also sets out an assumption about neoadjuvant treatment of early breast cancer. The full wording was not accessible to Synopulse.
- It is the third breast cancer medicine TLV has added this month. AstraZeneca‘s Truqap and Roche’s Itovebi entered the scheme from 1 September, Itovebi with a side agreement under which the company pays rebates to the regions.
Access read
A general subsidy across both settings is a clean result for Roche’s subcutaneous strategy, and it lands before pertuzumab biosimilars reach the market.
- Severity did the work. TLV scales what it will accept per quality-adjusted life year to the severity of the condition. Placing adjuvant use at high severity and metastatic use at very high severity let Phesgo clear the bar in both, without a restriction to one setting.
- The format is the defence. The CHMP backed the first pertuzumab biosimilar reviewed under a tailored clinical approach in September. Biosimilar pertuzumab is an intravenous single agent, so a switch away from Phesgo means returning to separate infusions of two antibodies. A subsidised subcutaneous combination is harder to displace on price alone.
- Roche has two breast cancer additions in Sweden in one month. Itovebi needed a rebate side agreement to reach an acceptable cost; TLV’s summary for Phesgo reports its cost per quality-adjusted life year below the usual level in both settings. The difference shows how much room a mature franchise has compared with a new launch.